Alterations in osteopontin modify muscle size in females in both humans and mice

Medicine and Science in Sports and Exercise

Volumn 45, Issue 6, 2013, Pages 1060-1068

  Hoffman, Eric P ^a   Gordish Dressman, Heather ^a   McLane, Virginia D ^b   Devaney, Joseph M ^a   Thompson, Paul D ^c   Visich, Paul ^d   Gordon, Paul M ^e   Pescatello, Linda S ^f   Zoeller, Robert F ^g   Moyna, Niall M ^h   Angelopoulos, Theodore J ⁱ   Pegoraro, Elena ^j   Cox, Gregory A ^k   Clarkson, Priscilla M ^l  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MAINE   (United States)

^c HARTFORD HOSPITAL   (United States)

^d UNIVERSITY OF NEW ENGLAND   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF CONNECTICUT   (United States)

^g FLORIDA ATLANTIC UNIVERSITY   (United States)

^h DUBLIN CITY UNIVERSITY   (Ireland)

ⁱ UNIVERSITY OF CENTRAL FLORIDA   (United States)

^j UNIVERSITY OF PADOVA   (Italy)

^k JACKSON LABORATORY   (United States)

^l UNIVERSITY OF MASSACHUSETTS   (United States)

more..

Author keywords

estrogen; genetic polymorphism; hypertrophy; MRI; Osteopontin (OPN); secreted phosphoprotein 1 (SPP1)

Indexed keywords

BIOLOGICAL MARKER; MYOGLOBIN; OSTEOPONTIN; SPP1 PROTEIN, MOUSE;

ADULT; ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BLOOD; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETICS; GENOTYPING TECHNIQUE; HISTOLOGY; HUMAN; KNOCKOUT MOUSE; MALE; MOUSE; MULTICENTER STUDY; MUSCLE STRENGTH; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PHYSIOLOGY; RESISTANCE TRAINING; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; STATISTICAL MODEL;

ADULT; ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL MARKERS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENOTYPING TECHNIQUES; HEALTHY VOLUNTEERS; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, KNOCKOUT; MUSCLE STRENGTH; MUSCLE, SKELETAL; MYOGLOBIN; OSTEOPONTIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RESISTANCE TRAINING; SEX FACTORS;

EID: 84878937718     PISSN: 01959131     EISSN: 15300315     Source Type: Journal    
DOI: 10.1249/MSS.0b013e31828093c1     Document Type: Article

References (40)

1. Akagi R, Takai Y, Kato E, et al. Relationships between muscle strength and indices of muscle cross-sectional area determined during maximal voluntary contraction in middle-aged and elderly individuals. J Strength Cond Res. 2009;23(4):1258-62.
2. Banerjee A, Apte UM, Smith R, Ramaiah SK. Higher neutrophil infiltration mediated by osteopontin is a likely contributing factor to the increased susceptibility of females to alcoholic liver disease. J Pathol. 2006;208(4):473-85.
3. Bollyky PL, Wu RP, Falk BA, et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A. 2011;108:7938-43.
4. Chen J, Zhao P, Massaro D, et al. The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res. 2004;32: D578-81.
5. Chen RX, Xia YH, Cui JF, Xue TC, Ye SL. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol. 2010;25:1435-42.
6. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sor-ensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphor-ylation and five O-glycosylation sites and their biological implications. Biochem J. 2005;390:285-92.
7. Clarkson PM, Devaney JM, Gordish-Dressman H, et al. ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J Appl Physiol. 2005a;99: 154-63.
8. Clarkson PM, Hoffman EP, Zambraski E, et al. ACTN3 and MLCK genotype associations with exertional muscle damage. J Appl Physiol. 2005b;99:564-9.
9. Craig AM, Denhardt DT. The murine gene encoding secreted phos-phoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene. 1991;100:163-71.
10. Devaney JM, Thompson PD, Visich PS, et al. The 1p13.3 LDL (C)-associated locus shows large effect sizes in young populations. Pediatr Res. 2011a;69:538-43.
11. Devaney JM, Gordish-Dressman H, Harmon BT, et al. AKT1 polymorphisms are associated with risk for metabolic syndrome. Hum Genet. 2011;129:129-39.
12. Ding Z, Wu CJ, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470:269-73.
13. Giacopelli F, Marciano R, Pistorio A, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics. 2004;20:87-96.
14. Glas J, Seiderer J, Bayrle C, et al. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease. PLoS One. 2011;6:e29309.
15. Han S, Guthridge JM, Harley IT, et al. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One. 2008;3:e0001757.
16. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919-28.
17. Hubal MJ, Devaney JM, Hoffman EP, et al. CCL2 and CCR2 polymorphisms are associated with markers of exercise-induced skeletal muscle damage. J Appl Physiol. 2010;108:1651-8.
18. Hubal MJ, Urso ML, Clarkson PM. Genetic aspects of muscular strength and size. In: Pescatello L, Roth SM, editors. Exercise Genomics. New York: Humana Press; 2011. pp. 157-78.
19. Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB. Age-and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun. 2009;10:487-94.
20. Keykhosravani M, Doherty-Kirby A, Zhang C, et al. 2005. Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry. 2005;44: 6990-7003.
21. Kim SM, Park YY, Park ES, et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010;5:e15074.
22. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer. 2011;10:15.
23. Kwon HJ, Won YS, Yoon WK, Nam KH, Kim DY, Kim HC. The role of osteopontin in D-galactosamine-induced liver injury in genetically obese mice. Toxicol Appl Pharmacol. 2010;242: 344-51.
24. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteo-pontin gene (spp1). J Clin Invest. 1998;101:1468-78.
25. Long AD, Langley CH. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res. 1999;8:720-31.
26. Minotti JR, Pillay P, Oka R, Wells L, Christoph I, Massie BM. Skeletal muscle size: relationship to muscle function in heart failure. J Appl Physiol. 1993;75(1):373-81.
27. Miyajima J, Hayashi T, Saito K, Iida S, Matsuoka K. The interaction between female sex hormone receptors and osteopontin in a rat hyperoxaluric model. Kurume Med J. 2010;57:73-80.
28. Mori R, Shaw TJ, Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med. 2008;205:43-51.
29. Nishimichi N, Hayashita-Kinoh H, Chen C, Matsuda H, Sheppard D, Yokosaki Y. Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1. J Biol Chem. 2011;286:11170-8.
30. Pegoraro E, Hoffman EP, Piva L, et al. Cooperative International Neuromuscular Research Group. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology. 2011;76:219-26.
31. Sayer AA, Syddall H, O'Dell SD, et al. Polymorphism of the IGF2 gene, birth weight and grip strength in adult men. Age Ageing. 2002;31:468-70.
32. Schrager MA, Roth SM, Ferrell RE, et al. Insulin-like growth factor-2 genotype, fat-free mass, and muscle performance across the adult life span. J Appl Physiol. 2004;97:2176-83.
33. Sewright KA, Hubal MJ, Kearns A, Holbrook MT, Clarkson PM. Sex differences in response to maximal eccentric exercise. Med Sci Sports Exerc. 2008;40(2):242-51.
34. Thompson PD, Moyna N, Seip R, et al. Functional polymorphisms associated with human muscle size and strength. Med Sci Sports Exerc. 2004;36(7):1132-9.
35. Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, Pagel CN. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol. 2008;40:2303-14.
36. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19: 333-45.
37. Yang N, MacArthur DG, Gulbin JP, et al. ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet. 2003;73:627-31.
38. Yokosaki Y, Matsuura N, Sasaki T, et al. The integrin alpha(9)-beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem. 1999;274:36328-34.
39. Zhao P, Iezzi S, Carver E, et al. Slug is a novel downstream target of MyoD. Temporal profiling in muscle regeneration. J Biol Chem. 2002;277:30091-101.
40. Zhao P, Caretti G, Mitchell S, et al. Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem. 2006;281:429-38.